공지 • Oct 23
Alexandria Co. For Pharmaceuticals & Chemical Industries announces Annual dividend, payable on November 06, 2025 Alexandria Co. For Pharmaceuticals & Chemical Industries announced Annual dividend of EGP 62.9500 per share payable on November 06, 2025, ex-date on November 04, 2025 and record date on November 05, 2025. 공지 • Sep 08
Alexandria Co. For Pharmaceuticals & Chemical Industries, Annual General Meeting, Sep 27, 2025 Alexandria Co. For Pharmaceuticals & Chemical Industries, Annual General Meeting, Sep 27, 2025, at 12:00 Egypt Standard Time. Location: cairo Egypt Board Change • May 14
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Declared Dividend • Nov 07
Dividend increased to ج.م30.00 Dividend of ج.م30.00 is 131% higher than last year. Ex-date: 18th November 2024 Payment date: 20th November 2024 Dividend yield will be 9.7%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is well covered by both earnings (23% earnings payout ratio) and cash flows (39% cash payout ratio). The dividend has increased by an average of 9.5% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 19% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ج.م296, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 147% over the past three years. 공지 • Sep 19
Alexandria Co. For Pharmaceuticals & Chemical Industries, Annual General Meeting, Oct 19, 2024 Alexandria Co. For Pharmaceuticals & Chemical Industries, Annual General Meeting, Oct 19, 2024, at 12:00 Egypt Standard Time. Location: cairo Egypt New Risk • Sep 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (ج.م1.15b market cap, or US$23.6m). New Risk • Jul 06
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (ج.م1.05b market cap, or US$22.0m). New Risk • Jun 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.03% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (ج.م1.09b market cap, or US$23.1m). Valuation Update With 7 Day Price Move • Feb 04
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ج.م235, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 8x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 103% over the past three years. Valuation Update With 7 Day Price Move • Nov 27
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ج.م182, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 9x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 72% over the past three years. Upcoming Dividend • Nov 06
Upcoming dividend of ج.م13.00 per share at 8.2% yield Eligible shareholders must have bought the stock before 13 November 2023. Payment date: 15 November 2023. Trailing yield: 8.2%. Within top quartile of Egyptian dividend payers (7.2%). Higher than average of industry peers (3.0%). New Risk • Sep 20
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (ج.م730.5m market cap, or US$23.6m). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • Nov 06
Upcoming dividend of ج.م12.20 per share Eligible shareholders must have bought the stock before 13 November 2022. Payment date: 15 November 2022. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 7.6%. Lower than top quartile of Egyptian dividend payers (9.9%). Higher than average of industry peers (4.5%). Reported Earnings • Sep 22
Full year 2022 earnings released Full year 2022 results: Revenue: ج.م1.22b (up 9.9% from FY 2021). Net income: ج.م129.0m (up 10% from FY 2021). Profit margin: 11% (in line with FY 2021). Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Buying Opportunity • Jan 13
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 20%. The fair value is estimated to be ج.م139, however is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% per annum over the last 3 years. Earnings per share has grown by 13% per annum over the last 3 years. Upcoming Dividend • Nov 01
Upcoming dividend of ج.م10.00 per share Eligible shareholders must have bought the stock before 08 November 2021. Payment date: 10 November 2021. Trailing yield: 10%. Within top quartile of Egyptian dividend payers (7.6%). Higher than average of industry peers (4.0%). Valuation Update With 7 Day Price Move • Aug 31
Investor sentiment improved over the past week After last week's 16% share price gain to ج.م155, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 20x in the Pharmaceuticals industry globally. Total returns to shareholders of 51% over the past three years. Major Estimate Revision • Apr 10
Consensus EPS estimates fall to ج.م24.70 The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from ج.م1.19b to ج.م1.14b. EPS estimate also fell from ج.م34.00 to ج.م24.70. Net income forecast to grow 6.8% next year vs 13% growth forecast for Pharmaceuticals industry in Egypt. Consensus price target down from ج.م290 to ج.م265. Share price was steady at ج.م134 over the past week. Is New 90 Day High Low • Mar 16
New 90-day low: ج.م134 The company is down 2.0% from a price of ج.م137 on 16 December 2020. Underperformed the Egyptian market, which is up 4.0% over the last 90 days. Lagged the Pharmaceuticals industry, which is up 6.0% over the same period. Simply Wall St's valuation model estimates the intrinsic value at ج.م179 per share. Is New 90 Day High Low • Feb 04
New 90-day high: ج.م144 The company is up 5.0% from its price of ج.م137 on 05 November 2020. The Egyptian market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م179 per share. Is New 90 Day High Low • Dec 21
New 90-day low: ج.م134 The company is down 7.0% from its price of ج.م145 on 22 September 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Is New 90 Day High Low • Nov 21
New 90-day low: ج.م135 The company is down 1.0% from its price of ج.م136 on 23 August 2020. The Egyptian market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Upcoming Dividend • Oct 26
Upcoming Dividend of ج.م15.50 Per Share Will be paid on the 4th of November to those who are registered shareholders by the 2nd of November. The trailing yield of 7.8% is below the top quartile of Egyptian dividend payers (11%), but it is higher than industry peers (6.0%).